Latest Options News

Mirrabooka Investments reports a 26% drop in net profit for FY25 but maintains its fully franked dividend, supported by a significant $85 million capital raise. The fund’s portfolio return lags the benchmark amid sector headwinds, yet long-term performance remains robust.

Viridis Mining and Minerals, through its Brazilian JV Viridion, has secured municipal land in Poços de Caldas to build Latin America’s first rare earth refining and recycling centre, backed by strong government support and aligned with Brazil’s critical minerals strategy.

Central Asia Metals Plc has made an unconditional all-cash offer to acquire New World Resources Limited at A$0.065 per share, a significant premium over recent prices and a superior bid to its rival. The New World board unanimously recommends shareholders accept the offer in the absence of a better proposal.

MLG Oz Limited has locked in a new two-year contract with Fortescue subsidiaries to provide crushing and screening services at multiple Western Australian mine sites, reinforcing its foothold in the mining services sector.

Genesis Minerals delivered record FY25 gold production, exceeding guidance, and completed a transformative A$250 million acquisition of Focus Minerals’ Laverton project, enhancing its ASPIRE 400 growth strategy.

betr Entertainment has unveiled an all-scrip takeover bid for PointsBet, offering shareholders 3.81 betr shares per PointsBet share, valuing the offer above a competing cash bid and promising significant cost synergies.

Rapid Critical Metals has completed its capital consolidation and placement, reshaping its issued capital structure with shareholder approval.

Clean Seas Seafood’s takeover by Yumbah Aquaculture has been formally approved and registered, marking a key milestone in the seafood sector consolidation. Share trading is suspended as shareholders prepare for compensation.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Imugene Limited has launched a A$37.5 million capital raising to advance its promising off-the-shelf CAR T therapy, azer-cel, following encouraging Phase 1b data showing a 75% overall response rate in lymphoma patients.

Imugene Limited has completed a $22.5 million institutional placement and launched a $15 million Share Purchase Plan, both featuring attaching options, to fund its azer-cel clinical program through a pivotal trial in 2026.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.